The following is the summary of “Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis” published in the November 2022 issue of Allergy and Clinical Immunology by Bousquet, et al.
Drug repurposing is a subfield of value-added medicine that is considered to be one of the most essential. It comprises investigating and assessing already available drugs for the possibility of novel therapeutic applications, aiming to satisfy unmet medical business needs.
In the realm of allergic rhinitis, there are a variety of unmet requirements that could be addressed by repurposing existing drugs. This could bring about a fundamental shift in how sickness is managed. The treatments currently available for allergic rhinitis center on continuous long-term treatment, and the pharmaceutical registration process is based on randomized controlled studies that have been carried out for at least 14 days and have had an adherence rate of at least 70%. In addition, an as-needed treatment based on the patient’s symptoms has been presented as an alternate strategy for treating allergic rhinitis.
The old continuous treatment is being abandoned in favor of this new approach. Existing clinical studies on as-needed treatment for allergic rhinitis will be discussed at this rostrum, along with real-world data obtained via the mobile health app MASK-air. MASK-air is focused on digitally-enabled, patient-centered care pathways, and its data will be presented.